Patents by Inventor Brooke Harrison

Brooke Harrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for inducing physiological hypertrophy
    Patent number: 9925162
    Abstract: Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition. In certain embodiments methods and compositions involve an aquaporin 7 inducer.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: March 27, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO
    Inventors: Leslie A. Leinwand, Cecilia Riquelme, Brooke Harrison, Jason Magida
  • METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY
    Publication number: 20150045433
    Abstract: Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition.
    Type: Application
    Filed: February 27, 2014
    Publication date: February 12, 2015
    Inventors: Leslie A. Leinwand, Cecilia Riquelme, Brooke Harrison, Jason Magida
  • METHODS AND COMPOSITIONS FOR INDUCING PHYSIOLOGICAL HYPERTROPHY
    Publication number: 20120142776
    Abstract: Methods and compositions are provided for inducing physiologic hypertrophy in a cell for treatment or prevention of a cardiovascular disease or condition.
    Type: Application
    Filed: October 13, 2011
    Publication date: June 7, 2012
    Inventors: Leslie A. Leinwand, Cecilia Riquelme, Brooke Harrison, Jason Magida
  • METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN
    Publication number: 20110171196
    Abstract: The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.
    Type: Application
    Filed: January 4, 2011
    Publication date: July 14, 2011
    Applicants: The Board of Regents of the University of Texas System, Gilead Sciences, Inc.
    Inventors: JOHANNES BACKS, BROOKE HARRISON, KHAI HUYNH, KEITH KOCH, TIMOTHY A. MCKINSEY, ERIC OLSON, NIKOS PAGRATIS
  • Methods of treatment and uses for CaMKII and its interaction with HDACs and calpain
    Patent number: 7863414
    Abstract: The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: January 4, 2011
    Assignees: The Board of Regents of the University of Texas Systems, Gilead Sciences, Inc.
    Inventors: Johannes Backs, Brooke Harrison, Khai Huynh, Keith Koch, Timothy A. McKinsey, Eric Olson, Nikos Pagratis
  • Methods of Treatment and Uses for CaMKII and Its Interaction with HDACs and Calpain
    Publication number: 20070142285
    Abstract: The present invention provides for methods of treating and cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension comprising the use of CaMKII-HDAC binding domains. The present invention discloses not only the fact that CaMKII binds to HDAC4 at a specific site, but that HDAC4 may dimerize with other HDACs. Both events can lead to export of HDACs from the nucleus to the cytoplasm, an event associated with the development of heart disease. Thus the methods of treatment and the screening methods of the present invention are novel attempts to prevent, treat or identify therapies for cardiac hypertrophy, heart failure, dilated cardiomyopathy or hypertension.
    Type: Application
    Filed: November 17, 2006
    Publication date: June 21, 2007
    Inventors: Johannes Backs, Brooke Harrison, Khai Huynh, Keith Koch, Timothy McKinsey, Eric Olson, Nikos Pagratis
  • Inhibition of protein kinase C-related kinase (PRK) as a treatment for cardiac hypertrophy and heart failure
    Publication number: 20050283841
    Abstract: The present invention provides for methods of treating and preventing cardiac hypertrophy and heart failure. MEF-2 and Class II HDACs have been shown to have a major role in cardiac hypertrophy and heart disease, and inhibition of class II HDAC's has been shown to have a beneficial, anti-hypertrophic effect. The present invention provides a link between MEF-2 and class II HDAC's, a kinase known as PRK. The present invention further demonstrates that inhibitors of PRK inhibit cardiac hypertrophy and heart disease by inhibiting, in part, the fetal cardiac gene expression and cellular reorganization that occurs when MEF-2 dependent transcription is activated.
    Type: Application
    Filed: February 2, 2005
    Publication date: December 22, 2005
    Inventors: Timothy McKinsey, Eric Olson, Brooke Harrison, Igor Rybkin, Steve Helmke